Use of Long-Acting Injectables for Severe Mental Illness in the Peripartum Period: A Case Report and a Scoping Review
Open Access
- 13 October 2024
- journal article
- Published by Springer Nature in Cureus
- Vol. 16 (10)
Abstract
The management of acute mania during pregnancy poses a complex clinical task, necessitating careful consideration of treatment options and demanding a delicate balance between the risks associated with medication use and the adverse impacts of untreated severe mental illness on the fetus. Medication nonadherence stands out as a significant factor contributing to relapse, with rates potentially reaching 40%. The pharmacokinetic profile of long-acting injectable (LAI) risperidone contrasts with that of oral risperidone, characterized by a gradual and consistent release from the depot, mitigating fluctuations between peak and trough concentrations. Clinically, this sustained plasma profile of LAI risperidone has been linked to a reduction in adverse events, such as extrapyramidal side effects, metabolic syndrome, and hyperprolactinemia. Numerous studies have indicated that LAI antipsychotic therapy correlates with reduced mortality rates and decreased number of hospitalizations. This case report illustrates the effective management of acute mania in a pregnant 32-year-old through the utilization of LAI risperidone. This case underscores the significance of individualized treatment strategies and emphasizes the potential utility of LAI antipsychotics as a viable therapeutic option for managing acute mania in pregnancy. Further research is warranted to delineate the long-term outcomes and safety profile of LAI antipsychotics in this population.Keywords
This publication has 11 references indexed in Scilit:
- Long-Acting Injectable Antipsychotic Treatment during Pregnancy: A Case SeriesInternational Journal of Environmental Research and Public Health, 2023
- Long-acting injectable antipsychotic treatment during pregnancy: Outcomes for women at a tertiary maternity hospitalPsychiatry Research, 2022
- Severe and persistent mental illness (SPMI) in pregnancy and breastfeeding: focus on second-generation long acting injectable antipsychoticsExpert Opinion on Drug Safety, 2021
- Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series reportTherapeutic Advances in Psychopharmacology, 2021
- Use of long acting injectable aripiprazole before and through pregnancy in bipolar disorder: a case reportBMC Pharmacology and Toxicology, 2019
- Antipsychotic use in pregnancyExpert Opinion on Pharmacotherapy, 2015
- PRISMA StatementEpidemiology, 2011
- Antipsychotic Therapy During Early and Late Pregnancy. A Systematic ReviewSchizophrenia Bulletin, 2008
- Use of long-acting injectable risperidone before and throughout pregnancy in schizophreniaProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2007
- Pregnancy Outcome of Women Using Atypical Antipsychotic DrugsThe Journal of Clinical Psychiatry, 2005